Philip Morris International shares retreated 1.4% during Monday's session, closing at $180.17. The stock moved between $179.85 and $182.54, trading approximately 1.6% below its 52-week peak of $183.16.
The decline occurred despite a series of analyst price target increases. Stifel lifted its target to $200 from $180, Citigroup raised to $210 from $200, and Morgan Stanley boosted to $205 from $175. UBS increased its target to $181.50 from $158 while maintaining a neutral rating.
Investor attention focused on competitive dynamics in the nicotine pouch market, where PMI's Zyn brand faces increasing rivalry. CEO Jacek Olczak recently emphasized Zyn's market leadership, though analysts noted growing competitive pressure in the U.S. segment.
The company filed an automatic shelf registration statement on Friday, providing flexibility to offer debt securities for purposes including debt repayment, working capital, acquisitions, or share buybacks. This followed PMI's updated 2026 profit guidance, which exceeded analyst expectations.
Market sentiment was further influenced by upcoming U.S. economic data, including delayed January nonfarm payrolls and consumer price index figures. Consumer staples stocks underperformed within the S&P 500 during the session.
PMI is scheduled to present at the Consumer Analyst Group of New York conference on February 18, offering investors another opportunity to assess the company's strategic direction following recent earnings.
